Retatrutide: What to Know Before You Chase the Next Weight Loss Drug

Retatrutide is an experimental weight loss drug from Eli Lilly. It is not approved, it is not legally for sale anywhere, and anything sold online as "reta" is not the drug from the trials. The trial results are real and they are big, which is exactly why the black market around it is growing. Here is what the numbers actually show, what the recent reports of deaths say, and what still does the work no matter what gets approved next year.

What retatrutide is

Retatrutide is a once-weekly injection that works on three hormone receptors at once: GLP-1, GIP and glucagon. Semaglutide (Ozempic, Wegovy) works on one. Tirzepatide (Mounjaro, Zepbound) works on two. Adding the third is the reason the weight loss numbers in the trials are higher than anything on the market today.

It is being tested in a set of Phase 3 trials Lilly calls TRIUMPH. Lilly has said it plans to file with the FDA in the first quarter of 2027. Filing is not approval. Until the FDA reviews it, the only legal way to take retatrutide is inside a clinical trial.

What the trials showed

The largest trial, TRIUMPH-1, followed 2,339 adults with obesity or overweight and at least one weight-related condition, none of them with diabetes, for 80 weeks. Average weight loss was 19.0 percent on the lowest dose, 25.9 percent on the middle dose and 28.3 percent on the highest dose. A smaller group that stayed on the top dose for 104 weeks averaged 30.3 percent.

The numbers were lower, and still large, in the other two trials Lilly has reported. In adults with type 2 diabetes, weight loss ran from 12.7 to 20.8 percent against 4.0 percent on placebo. In adults with severe obesity and heart disease, 21.6 to 22.6 percent against 3.2 percent on placebo.

Three things get left out of the headlines. First, these were supervised studies: doses were raised slowly, people were monitored, and the drug they received was the real thing at a known strength. Second, the side effects were common. In TRIUMPH-1, nausea hit up to 42 percent of people on the top dose, diarrhea about one in three, vomiting one in four, and 11.3 percent of the top-dose group stopped because of side effects. Third, 80 weeks is a year and a half. The trials measure what happens on the drug. They do not tell you what happens to a person who stops it, and with every drug in this class so far, the weight tends to come back for people who stop without having changed how they eat, move and sleep.

It is not approved, and you cannot buy it legally

There is no prescription for retatrutide. There is no compounded version. No clinic, med spa, pharmacy or website can legally sell it to you today. Lilly has said it will seek approval in early 2027; FDA review after filing typically takes months, not days. If a seller tells you otherwise, that alone tells you what you need to know about the seller.

The black-market "reta" problem

On October 13, CBS News reported that the FDA had received two reports of deaths after people took products sold as retatrutide. The records came from the FDA's adverse event reporting system through a public records request. In one, reported in July, a 41-year-old woman went into cardiac arrest after using a product from what the report called an unreliable source. In the other, reported in September, a 49-year-old died of cardiac arrest after severe dehydration and malnutrition; the report says a licensed nurse sold her the vials from an online peptide vendor and recommended the doses.

Neither death has been confirmed as caused by the product, and the FDA has not said whether it verified the reports. What is not in doubt is where the products came from. Lilly says it has tested suspect products and found the wrong amount of active ingredient and contaminants, has sued sellers, and has reported more than 14,000 online listings to authorities. Vials labeled as retatrutide have turned up at online "research peptide" shops, at med spas, and, according to the reporting, in corner stores in Brooklyn.

The label on most of these products says "for research use only" or "not for human consumption." That is not a formality. It means nobody checked what is in the vial, how much of it there is, or whether it is sterile.

Three mistakes people make with a drug like this

Treating a trial headline like a product you can order. The 28 percent number belongs to people who got the real compound, at a measured dose, with a medical team watching. None of that comes in an envelope from a peptide site.

Trusting the seller because a nurse, a coach or an influencer vouched for the dosing. One of the two deaths in the FDA reports involved exactly that. A credential does not change what is in the vial.

Assuming a stronger drug means the habits matter less. It is the opposite. The bigger the loss, the more muscle is at risk and the more a person has to be able to eat, train and sleep well on their own afterward. The drug can lower appetite. It cannot build the routine that keeps the weight off when the appetite comes back.

What matters more than retatrutide

Whether someone is on a GLP-1 today, waiting for the next one, or never touching any of them, the same five things decide what the scale does over years rather than months.

Protein at every meal, because losing weight fast without it means losing muscle along with fat. Strength training two to four days a week, because muscle is what keeps your metabolism, your strength and your independence as you age. Daily steps, because walking is the easiest calorie burn to sustain and the one people drop first. Sleep, because a short night raises hunger and lowers willpower the next day. And a calorie deficit you can actually hold, which usually means smaller than the one you want to start with.

None of that needs a prescription, and none of it changes when a new drug is approved. It is also the part most people skip, which is why they end up back where they started after every diet, every pill and every injection.

If you are on a GLP-1 now, or thinking about one

Talk to your doctor about the approved options or a clinical trial if you want to explore the drug side. That is their job, not ours. Our job is the other side: making sure that if you lose weight, you keep your muscle, keep your strength, and come out of it with habits that hold. That is what our coaching alongside a GLP-1 is built for, and it is the same approach we use with every client, especially after 40.

If you want to see what that looks like for you, book a free 30-minute call with a coach. If you would rather start on your own, the free weekly workout plan is a good first step.

Stay Consistent,
Brian

HPHGenetics provides fitness coaching and education, not medical advice. Talk with your doctor before starting, stopping or combining any medication.

Sources for this post

• Eli Lilly press release, July 23, 2026 (TRIUMPH-2 and TRIUMPH-3 results, side effects, plan to file with the FDA in Q1 2027)
• AJMC, May 21, 2026 (TRIUMPH-1: 2,339 adults, 80 weeks, 19.0 to 28.3 percent, 30.3 percent at 104 weeks, side effects)
• Becker's Hospital Review, October 13, 2026, reporting CBS News (the two FDA adverse-event reports, Lilly's statements and lawsuits)
• Newsweek, October 14, 2026 and Futurism, October 17, 2026 (follow-up coverage of the black-market trade)